Synergistic administration of anti-CD19 CAR T cells and ibrutinib in mice bearing ALL and CLL led to enhanced engraftment, tumor clearance, and survival [92]. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.